Safety Monitoring System for the Malaria Vaccine Implementation Programme (MVIP)

The Food and Drugs Authority (FDA) has received a number of queries about the systems in place to prevent, detect and respond to possible safety issues that might arise from use of the Mosquirix malaria vaccine during the Malaria Vaccine Implementation Programme (MVIP).

The FDA, in collaboration with the Expanded Programme on Immunization (EPI) of the Ghana Health Service has instituted proactive measures to monitor the MVIP and continues to strengthen the capacity of healthcare personnel involved in the vaccination. These measures will ensure that any adverse events following immunization (side effects) are promptly identified and reported to the FDA through its established Safety Monitoring System.

Selected healthcare professionals have also been specifically trained by the FDA and EPI and resourced by the Ghana Health Service to visit healthcare facilities in vaccinating districts to monitor, detect and report safety issues that are suspected to have occurred after receiving the Mosquirix Vaccine.

Any such side effects will be promptly investigated and assessed by the FDA’s independent Technical Advisory Expert Committees for causal relationship to the vaccine and recommendations made to the Ghana Health Service. This will ensure utmost safety of our children.

The FDA wishes to assure the public that it continuously monitors all registered vaccines and medicines to ensure approved standards are maintained.

The public is always encouraged to report any suspected safety issues to any regulated product to the FDA to enable the necessary regulatory actions to be taken.

Reports are promptly responded to and can be made through any of the following means:

- Hotline: 0299 802 933
- WhatsApp: 0206 973 065
- Mobile: 0244 310 297
- Email: drug.safety@fdaghana.gov.gh

FDA...Your Wellbeing, Our Priority

Signed
DELESE A. A. DARKO (MRS)
CHIEF EXECUTIVE OFFICER, FDA